Video

Dr. Albala on Patient Selection for Robotic Surgery in Prostate Cancer

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses patients with prostate cancer who are best suited to be treated with robotic surgery.

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses patients with prostate cancer who are best suited to be treated with robotic surgery.

According to Albala, all patients who are surgical candidates for the procedure that they're going to undergo, can be done robotically. If a patient is a candidate for a prostatectomy—whether the procedure is done with a retropubic, perineal, or a robotic approach—then they can be operated on robotically.

Obese patients can be be treated with robotic surgery with the new da Vinci system, which includes longer reaches for the instruments, explains Albala. Despite challenges with some of the earlier porotypes of the robot, these procedures are now able to be done with great ease and yield beneficial results for patients. Overall, anything that can be accomplished with an open procedure, he says, can also be done robotically.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic